Cambridge Healthtech Institute’s 14th Annual

Liquid Biopsy

Enabling Precision Oncology for Diagnostics and Drug Development

March 26-27, 2024

Liquid biopsy is a maturing technology for early detection of disease, patient stratification and therapy selection, monitoring response to therapy, and detecting disease recurrence. Cambridge Healthtech Institute’s 14th Annual Liquid Biopsy meeting will explore the latest technologies in detection and molecular characterization of CTCs, cell-free circulating tumor DNA (cfDNA), and circulating extracellular RNA, exosomes, and microvesicles, as well as the applications of liquid biopsy in diagnostics and drug development.

Coverage will include, but is not limited to:

Cancer screening and early detection
Liquid biopsy for minimal residual disease detection
Technology update in liquid biopsy detection and characterization
Applications of cell-free DNA and RNA as biomarkers in drug development
Liquid biopsy biomarkers for precision oncology
Exosomes and microvesicles as biomarkers
Predicting immunotherapy response through circulating immune cells
Liquid biopsy for companion diagnostics

The deadline for priority consideration is September 1, 2023.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: